Sinovac / REUTERS
China has approved emergency use of Sinovac Biotech's COVID-19 vaccine in people aged between three and 17, its chairman Yin Weidong told state TV late on Friday.
That's according to Reuters.
It is noted China's mass vaccination drive, which administered 723.5 million doses of vaccines as of June 3, is currently only open to those aged 18 and above.
When Sinovac's vaccine will be offered to younger groups depends on health authorities formulating China's inoculation strategies, Yin told state TV in an live interview.
Read also Tokyo Games could lead to Olympic coronavirus variant – media Yin said minors have lower priority for vaccination against the coronavirus compared with the elderly, who face higher risk of severe symptoms after infection.
Preliminary results from Phase I and II clinical trials showed the vaccine could trigger immune response in three to 17 year-old participants, and most adverse reactions were mild.
Sinovac has also completed a Phase II clinical trial where participants were injected with a third booster dose after completing two regular shots, Yin said.
Participants saw 10 fold increase in antibody levels compared with previous levels in a week, and 20 fold in half a month, Yin said.
Yin cautioned that Sinovac still needs to complete longer-term observation of antibody duration before it can make recommendation to authorities about when a third dose should be given.
More news reports
- U.S. to send another 20 million doses of COVID-19 vaccines to other countries
- No agreement yet on EU vaccine passports – media
- EU to reopen borders for fully vaccinated tourists from third countries
- Ukraine sends almost 200 oxygen concentrators to India (Photos)
Reporting by UNIAN